Business
Mammalian Display video
Fusion Antibodies plc is announcing the upcoming commercial launch of its OptiMAL® Human Antibody Discovery platform, featuring a video explaining its Mammalian Display technology, which boasts over 70% transduction efficiency and supports libraries exceeding 10⁹ variants, significantly outperforming competitor platforms. The company will also host a pre-recorded presentation and Q&A session on December 16, 2025, to discuss the launch, with no new material information expected. Investors are encouraged to submit questions via the company's Investor Hub. Disclaimer*
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\nREACH - Non-regulatory announcement*\n \n11 December 2025\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nMammalian Display video\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that ahead of the commercial launch of the OptiMAL® Human Antibody Discovery platform at the Antibody Engineering and Technology conference in San Diego on 15 December 2025, Fusion has prepared a short video of Dr Richard Buick, CSO, explaining some of the features, science and technology behind the Company's Mammalian Display technology. The technology has been combined with Fusion's Opti-library to create the OptiMAL® library. OptiMAL® is intended to be used to discover novel human antibodies against any target. The mammalian display platform library design and method is protected by US patent US12378696. The Mammalian Display technology can also be used with other antibody libraries.\n \nThe video can be viewed on the Investor Hub section of Fusion's website at, https://investorhub.fusionantibodies.com/s/7ea305.\n \nOther Mammalian Display technologies are available and have been summarised in the scientific literature e.g. Slavny P, Hegde M, Doerner A, Parthiban K, McCafferty J, Zielonka S and Hoet R (2024) Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects. Front. Immunol. 15:1469329. doi: 10.3389/fimmu.2024.1469329.\n \nFusion Antibodies has compared its own Mammalian Display technology to the competitor platforms in the review article and identified several superior advantages. The most significant are its transduction efficiency of over 70% and its ability to support very large libraries, exceeding 10⁹ variants. These are summarised in the table below:\n \n \n\n\n\n\nTechnology\n\n\nOptiMAL®\n\n\nRetrocyte Display\n\n\nOther Lentiviral mammalian display\n\n\nTransposase-mediated integration\n\n\nNuclease-directed integration\n\n\nRecombinase-mediated integration\n\n\n\n\nIntegration Efficiency\n\n\n>70%\n\n\n<5%\n\n\n0.5-5%\n\n\n6-7.5%\n\n\n0.5-5%\n\n\n1.7%\n\n\n\n\nReported library sizes\n\n\n>109\n\n\n106-108\n\n\n106\n\n\n106\n\n\n106-108\...